[ad_1]
Preston Klbaden, MD, Head of Research and Development at Arena Pharmaceuticals, discusses the results of a recent study presented at DDW 2019, which examined correlations between fecal calprotection and c-reactive protein and clinical outcomes in patients with ulcerative colitis taking eczasimod.
Source link
